{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:35:46Z","timestamp":1794512146821,"version":"4.9.1"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004338","name":"Saint Joseph University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.cyto.2022.155899","type":"journal-article","created":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:52:51Z","timestamp":1651319571000},"page":"155899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pirfenidone mitigates TGF-\u03b21-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model"],"prefix":"10.1016","volume":"154","author":[{"given":"Habib","family":"Layoun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joelle","family":"Hajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youakim","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Smayra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Habr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.cyto.2022.155899_b0005","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/ard.2008.093161","article-title":"Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences","volume":"68","author":"Bernatsky","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0738-081X(88)90044-2","article-title":"History and classification of polymyositis and dermatomyositis","volume":"6","author":"Bohan","year":"1988","journal-title":"Clin. Dermatol."},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/ijms18051084","article-title":"Idiopathic inflammatory myopathies: a review of the classification and impact of pathogenesis","volume":"18","author":"Mandel","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2022.155899_b0020","article-title":"Assessing functional performance in the mdx mouse model","volume":"85","author":"Aartsma-Rus","year":"2014","journal-title":"J. Visual. Experim. : JoVE"},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0025","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0030","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J. Rheumatol."},{"issue":"136","key":"10.1016\/j.cyto.2022.155899_b0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur. Respirat. Rev.: Off. J. Eur. Respirat. Soc."},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccm.2019.05.004","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"40","author":"Long","year":"2019","journal-title":"Clin. Chest Med."},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0045","first-page":"269","article-title":"Classification of myositis, nature reviews","volume":"14","author":"Lundberg","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2022.155899_b0050","doi-asserted-by":"crossref","unstructured":"V. Cottin, F. Thivolet-Bejui, M. Reynaud-Gaubert, J. Cadranel, P. Delaval, P.J. Ternamian, J.F. Cordier, P. Groupe d'Etudes et de Recherche sur les Maladies \u201cOrphelines, Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis, Eur. Respirat. J. 22(2) (2003) 245\u2013250.","DOI":"10.1183\/09031936.03.00026703"},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0055","first-page":"290","article-title":"Autoantibodies in myositis, nature reviews","volume":"14","author":"McHugh","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2022.155899_b0060","doi-asserted-by":"crossref","unstructured":"Y. Hamaguchi, M. Fujimoto, T. Matsushita, K. Kaji, K. Komura, M. Hasegawa, M. Kodera, E. Muroi, K. Fujikawa, M. Seishima, H. Yamada, R. Yamada, S. Sato, K. Takehara, M. Kuwana, Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome, PloS one 8(4) (2013) e60442.","DOI":"10.1371\/journal.pone.0060442"},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0065","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11926-018-0731-7","article-title":"Management of interstitial lung disease in patients with myositis specific autoantibodies","volume":"20","author":"Mecoli","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"issue":"131","key":"10.1016\/j.cyto.2022.155899_b0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1183\/09059180.00009113","article-title":"Interstitial lung disease","volume":"23","author":"Antoniou","year":"2014","journal-title":"Eur. Respirat. Rev.: Off. J. Eur. Respirat. Soc."},{"issue":"9779","key":"10.1016\/j.cyto.2022.155899_b0075","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(11)60546-1","article-title":"Pirfenidone for idiopathic pulmonary fibrosis","volume":"377","author":"Bouros","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cyto.2022.155899_b0080","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1183\/09031936.00006610","article-title":"Idiopathic pulmonary fibrosis and pirfenidone","volume":"35","author":"Collard","year":"2010","journal-title":"Eur. Respirat. J."},{"key":"10.1016\/j.cyto.2022.155899_b0085","doi-asserted-by":"crossref","unstructured":"T.E. King, Jr., W.Z. Bradford, S. Castro-Bernardini, E.A. Fagan, I. Glaspole, M.K. Glassberg, E. Gorina, P.M. Hopkins, D. Kardatzke, L. Lancaster, D.J. Lederer, S.D. Nathan, C.A. Pereira, S.A. Sahn, R. Sussman, J.J. Swigris, P.W. Noble, A.S. Group, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, New Engl. J. Med. 370(22) (2014) 2083\u20132092.","DOI":"10.1056\/NEJMoa1402582"},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"The Lancet. Respirat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0095","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials","volume":"47","author":"Noble","year":"2016","journal-title":"Eur. Respirat. J."},{"key":"10.1016\/j.cyto.2022.155899_b0100","doi-asserted-by":"crossref","unstructured":"P.W. Noble, C. Albera, W.Z. Bradford, U. Costabel, M.K. Glassberg, D. Kardatzke, T.E. King, Jr., L. Lancaster, S.A. Sahn, J. Szwarcberg, D. Valeyre, R.M. du Bois, C.S. Group, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet 377(9779) (2011) 1760\u20131769.","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"10.1016\/j.cyto.2022.155899_b0105","doi-asserted-by":"crossref","unstructured":"H. Taniguchi, M. Ebina, Y. Kondoh, T. Ogura, A. Azuma, M. Suga, Y. Taguchi, H. Takahashi, K. Nakata, A. Sato, M. Takeuchi, G. Raghu, S. Kudoh, T. Nukiwa, J. Pirfenidone Clinical Study Group in, Pirfenidone in idiopathic pulmonary fibrosis, Eur. Respirat. J., 35(4) (2010) 821\u2013829.","DOI":"10.1183\/09031936.00005209"},{"issue":"153","key":"10.1016\/j.cyto.2022.155899_b0110","doi-asserted-by":"crossref","first-page":"190022","DOI":"10.1183\/16000617.0022-2019","article-title":"Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis","volume":"28","author":"Collins","year":"2019","journal-title":"Eur. Respirat. Rev.: Off. J. Eur. Respirat. Soc."},{"key":"10.1016\/j.cyto.2022.155899_b0115","doi-asserted-by":"crossref","first-page":"33226","DOI":"10.1038\/srep33226","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"The Lancet. Respirat. Med."},{"key":"10.1016\/j.cyto.2022.155899_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105700","article-title":"Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3)","volume":"74","author":"Wu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cyto.2022.155899_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12931-019-1093-z","article-title":"Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-beta1","volume":"20","author":"Jin","year":"2019","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s10020-020-00173-3","article-title":"Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt\/GSK-3beta\/beta-catenin and TGF-beta1\/Smad2\/3 signaling pathways","volume":"26","author":"Lv","year":"2020","journal-title":"Mol. Med."},{"issue":"11","key":"10.1016\/j.cyto.2022.155899_b0145","first-page":"14457","article-title":"Development of an improved animal model of experimental autoimmune myositis","volume":"8","author":"Kang","year":"2015","journal-title":"Int. J. Clin. Exp. Path."},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0150","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1177\/0961203321995254","article-title":"New insights in gut-liver axis in wild-type murine imiquimod-induced lupus","volume":"30","author":"Maalouly","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.cyto.2022.155899_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.106051","article-title":"Beneficial role of simvastatin in experimental autoimmune myositis","volume":"79","author":"Maalouly","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nm.1916","article-title":"Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle","volume":"15","author":"Bellinger","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.cyto.2022.155899_b0165","doi-asserted-by":"crossref","unstructured":"S.G. Julien, S.Y. Kim, R. Brunmeir, J.R. Sinnakannu, X. Ge, H. Li, W. Ma, J. Yaligar, B.P. Kn, S.S. Velan, P.V. Roder, Q. Zhang, C.K. Sim, J. Wu, M. Garcia-Miralles, M.A. Pouladi, W. Xie, C. McFarlane, W. Han, F. Xu, Narciclasine attenuates diet-induced obesity by promoting oxidative metabolism in skeletal muscle, PLoS Biol. 15(2) (2017) e1002597.","DOI":"10.1371\/journal.pbio.1002597"},{"issue":"1\u20132","key":"10.1016\/j.cyto.2022.155899_b0170","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-0270(95)00049-6","article-title":"Quantitative measurement of muscle strength in the mouse","volume":"62","author":"Smith","year":"1995","journal-title":"J. Neurosci. Methods"},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0363-5023(85)80210-0","article-title":"Effect of elbow position on grip and key pinch strength","volume":"10","author":"Mathiowetz","year":"1985","journal-title":"J. Hand Surg."},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0166-4328(97)87582-1","article-title":"Muscle activity during forelimb reaching movements in rats","volume":"85","author":"Hyland","year":"1997","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.5014\/ajot.46.6.509","article-title":"The relationship between elbow position and grip strength","volume":"46","author":"Kuzala","year":"1992","journal-title":"Am. J. Occupant. Ther.: Off. Publ. Am. Occupat. Ther. Associat."},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9440(10)64205-8","article-title":"Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation","volume":"161","author":"Cataldo","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.cyto.2022.155899_b0195","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.4049\/jimmunol.175.4.2589","article-title":"Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation","volume":"175","author":"Gueders","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2022.155899_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.566953","article-title":"CXCR1 and CXCR2 inhibition by ladarixin improves neutrophil-dependent airway inflammation in mice","volume":"11","author":"Mattos","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2022.155899_b0205","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","article-title":"Simple method of estimating severity of pulmonary fibrosis on a numerical scale","volume":"41","author":"Ashcroft","year":"1988","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.cyto.2022.155899_b0210","doi-asserted-by":"crossref","unstructured":"R.H. Hubner, W. Gitter, N.E. El Mokhtari, M. Mathiak, M. Both, H. Bolte, S. Freitag-Wolf, B. Bewig, Standardized quantification of pulmonary fibrosis in histological samples, BioTechniques 44(4) (2008) 507\u2013511, 514-7.","DOI":"10.2144\/000112729"},{"key":"10.1016\/j.cyto.2022.155899_b0215","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40248-017-0089-0","article-title":"Longitudinal assessment of bleomycin-induced lung fibrosis by Micro-CT correlates with histological evaluation in mice","volume":"12","author":"Ruscitti","year":"2017","journal-title":"Multidiscipl. Respirat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/labinvest.2014.135","article-title":"Treatment with CA-074Me, a Cathepsin B inhibitor, reduces lung interstitial inflammation and fibrosis in a rat model of polymyositis","volume":"95","author":"Zhang","year":"2015","journal-title":"Laborat. Investigat. J. Tech. Methods Pathol."},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0225","doi-asserted-by":"crossref","first-page":"L376","DOI":"10.1152\/ajplung.00311.2019","article-title":"Modeling pulmonary fibrosis through bleomycin delivered by osmotic minipump: a new histomorphometric method of evaluation, American journal of physiology","volume":"318","author":"Ravanetti","year":"2020","journal-title":"Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.cyto.2022.155899_b0230","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3389\/fphar.2020.01117","article-title":"Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography","volume":"11","author":"Ruscitti","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2022.155899_b0235","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fmed.2017.00118","article-title":"Exploring animal models that resemble idiopathic pulmonary fibrosis","volume":"4","author":"Tashiro","year":"2017","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0240","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coph.2010.03.001","article-title":"Inflammatory muscle diseases: a critical review on pathogenesis and therapies","volume":"10","author":"Dalakas","year":"2010","journal-title":"Curr. Opin. Pharmacol."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.155899_b0250","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40674-018-0110-6","article-title":"Myositis-related interstitial lung diseases: diagnostic features, treatment, and complications","volume":"5","author":"Shappley","year":"2019","journal-title":"Curr. Treatm. Options Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2022.155899_b0255","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0260","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejim.2013.01.002","article-title":"Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome","volume":"24","author":"Marie","year":"2013","journal-title":"Eur. J. Int. Med."},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0265","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.cyto.2022.155899_b0270","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients","volume":"10","author":"Suzuki","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"18","key":"10.1016\/j.cyto.2022.155899_b0275","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMra1402225","article-title":"Inflammatory muscle diseases","volume":"372","author":"Dalakas","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cyto.2022.155899_b0280","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/rheumatology\/keu258","article-title":"Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease","volume":"53","author":"Gono","year":"2014","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0285","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/rheumatology\/kez301","article-title":"Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis\/dermatomyositis-interstitial lung disease","volume":"59","author":"Matsuda","year":"2020","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0290","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/art.10794","article-title":"Interstitial lung disease in polymyositis and dermatomyositis","volume":"47","author":"Marie","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-beta: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat. Rev. Nephrol."},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0300","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1165\/rcmb.2005-0452OC","article-title":"Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge","volume":"35","author":"Hirano","year":"2006","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"5","key":"10.1016\/j.cyto.2022.155899_b0305","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0310","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.jtcvs.2005.04.012","article-title":"Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model","volume":"130","author":"Liu","year":"2005","journal-title":"J. Thoracic Cardiovasc. Surg."},{"issue":"4","key":"10.1016\/j.cyto.2022.155899_b0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1094-5539(03)00026-9","article-title":"Inhibition of experimental acute pulmonary inflammation by pirfenidone","volume":"16","author":"Spond","year":"2003","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2022.155899_b0320","doi-asserted-by":"crossref","unstructured":"K.W. Lee, T.H.t. Everett, D. Rahmutula, J.M. Guerra, E. Wilson, C. Ding, J.E. Olgin, Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure, Circulation 114(16) (2006) 1703\u20131712.","DOI":"10.1161\/CIRCULATIONAHA.106.624320"},{"issue":"1\u20133","key":"10.1016\/j.cyto.2022.155899_b0325","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2022.155899_b0330","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.toxlet.2018.10.019","article-title":"Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model","volume":"300","author":"Guo","year":"2019","journal-title":"Toxicol. Lett."},{"issue":"10","key":"10.1016\/j.cyto.2022.155899_b0335","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/rheumatology\/keh723","article-title":"Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis","volume":"44","author":"Kang","year":"2005","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cyto.2022.155899_b0340","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun. Rev."},{"issue":"6958","key":"10.1016\/j.cyto.2022.155899_b0345","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signalling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cyto.2022.155899_b0350","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1681\/ASN.2009121244","article-title":"Smad2 protects against TGF-beta\/Smad3-mediated renal fibrosis","volume":"21","author":"Meng","year":"2010","journal-title":"J. Am. Soc. Nephrol. : JASN"},{"issue":"4","key":"10.1016\/j.cyto.2022.155899_b0355","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.3892\/ijmm.2016.2705","article-title":"miR221 targets HMGA2 to inhibit bleomycininduced pulmonary fibrosis by regulating TGFbeta1\/Smad3-induced EMT","volume":"38","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Med."},{"issue":"3","key":"10.1016\/j.cyto.2022.155899_b0360","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial-mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.cyto.2022.155899_b0365","doi-asserted-by":"crossref","first-page":"L887","DOI":"10.1152\/ajplung.00397.2010","article-title":"TGFbeta signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment, American journal of physiology","volume":"300","author":"Degryse","year":"2011","journal-title":"Lung Cell. Mol. Physiol."},{"issue":"35","key":"10.1016\/j.cyto.2022.155899_b0370","doi-asserted-by":"crossref","first-page":"13180","DOI":"10.1073\/pnas.0605669103","article-title":"Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix","volume":"103","author":"Kim","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.cyto.2022.155899_b0375","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.200903-0322OC","article-title":"Contribution of epithelial-derived fibroblasts to bleomycin-induced lung fibrosis","volume":"180","author":"Tanjore","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622001089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:45:47Z","timestamp":1760910347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622001089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":75,"alternative-id":["S1043466622001089"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155899","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pirfenidone mitigates TGF-\u03b21-mediated fibrosis in an idiopathic inflammatory myositis-associated interstitial lung disease model","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.155899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155899"}}